NCT02313623Completed
MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
The investigators hypothesize that this single-cell analysis can be used to evaluate prostate needle-core biopsies prospectively even in non-homogenous samples by providing profiles of proteomic and phenotypic signatures. These profiles will in turn enable better predictions of the malignant progression of prostate cancers in the settings of current clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 7 Dec 2014
- Start date
- 1 Jul 2013
- Primary completion date
- 1 Oct 2025
- Lead sponsor
- Yale University
- Diseases
- Prostate cancer
- NCT number
- NCT02313623
What you commit to
- Study type: Observational
- Planned participants: 600
- From 1 Jul 2013 to the primary completion date, 1 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Any subjects that are unable to provide informed consent will be excluded
Who the study is looking for
- Only subjects that have scheduled Artemis prostate biopsy with defined regions of interest will be included in this study
Age in the registry: 18 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yale University Coordinator of this site? Confirm its status | New Haven | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.